Healthcare Industry News: RaySearch Laboratories
News Release - October 22, 2007
TomoTherapy Incorporated Announces Strategic Collaboration with RaySearch LaboratoriesMADISON, Wis.--(HSMN NewsFeed)--TomoTherapy Incorporated (NASDAQ: TTPY ) today announced a new software licensing, marketing and development agreement with RaySearch Laboratories. Under the agreement, a suite of software products will be developed to facilitate the transfer of radiation therapy treatment plans between TomoTherapy® Hi·Art® treatment systems and conventional linear accelerators, and to extend the Hi·Art system’s treatment planning functionality. These developments will lead to improved workflow coordination, more efficient product utilization and increased patient treatment capacity.
Said RaySearch CEO, Johan Löf, “We are pleased that today we can announce a new collaboration agreement with TomoTherapy Incorporated. TomoTherapy uses a highly innovative technology and is a rapidly growing supplier of radiotherapy equipment. The selection of RaySearch as a partner is further confirmation that we are the leading player in advanced software for radiotherapy.”
About RaySearch Laboratories
RaySearch Laboratories is a medical technology company developing advanced software solutions for improved radiation therapy of cancer. RaySearch’s products are sold through license agreements with leading partners such as Philips, Varian Medical Systems, Nucletron, Scanditronix-Wellhöfer and TomoTherapy. Six products have been launched to date and RaySearch’s software is used at over 1,200 clinics in more than 30 countries. In addition, existing agreements cover more than 15 other products that are scheduled to be launched in the coming years. RaySearch was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the company is listed in the Mid Cap segment on the OMX Nordic Exchange. For more information about RaySearch, please visit www.raysearchlabs.com.
About TomoTherapy Incorporated
TomoTherapy Incorporated has developed, manufactures and sells the TomoTherapy® Hi·Art® treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers. The Hi·Art treatment system combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The company completed its initial public offering in May 2007 and its stock is traded on the NASDAQ Global Market under the symbol TTPY. To learn more about TomoTherapy, please visit our Web site at www.TomoTherapy.com.
Statements in this release regarding future products, events, expectations and other similar matters, including but not limited to statements using the terms “can,” “will” or “expect” constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements contained in this press release are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated, including but not limited to risks inherent in the development and commercialization of new technology and products, and the other risks listed from time to time in TomoTherapy’s filings with the U.S. Securities and Exchange Commission, which by this reference are incorporated herein. These forward-looking statements represent TomoTherapy’s judgments as of this date of this press release. TomoTherapy assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events or otherwise.
©2007 TomoTherapy Incorporated. All rights reserved. TomoTherapy, the TomoTherapy logo and Hi·Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.